Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Rajendrakumar H. Jani"'
1
Akademický článek
A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.
Autor: Alka Deshpande, Harsh Toshniwal, Shashank Joshi, Rajendrakumar H Jani
Publikováno v: PLoS ONE, Vol 11, Iss 1, p e0146222 (2016)
OBJECTIVE:This study was designed to explore the efficacy and safety of saroglitazar 4 mg on hypertriglyceridemia in patients with HIV associated lipodystrophy. METHODS:During this 12-week prospective, multi-centric, open-label, single arm explorator
Externí odkaz: https://doaj.org/article/29c25c7a2067490da6337f77433d02b9
Zobrazit plný text záznamu
4
A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V)
Autor: Satinath Mukhopadhyay, Patel Pankaj Ramanbhai, Vikas Pai, Anil Bhansali, Shashank R Joshi, Rajendrakumar H. Jani, V. Shankar, Gambhire Dhiraj, Dinesh Kamath, A Paneerselvam
Publikováno v: Journal of Diabetes Science and Technology
Background: Dual PPARα/γ can improve both metabolic effects and minimized the side effects caused by either PPARα or PPARγ agonist. The PRESS V study was aimed to evaluate the safety, tolerability, and efficacy of saroglitazar 2 mg and 4 mg capsu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9ccd9d08e10d6dd8bfb53d745484db6
https://doi.org/10.1177/1932296813518680
Zobrazit plný text záznamu
5
Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
Autor: Kevinkumar Kansagra, Mukul R. Jain, Harilal Patel, Rajendrakumar H. Jani
Publikováno v: Clinical Drug Investigation
Background and Objectives Dyslipidaemia is a major cardiovascular risk factor associated with type 2 diabetes mellitus. Saroglitazar (ZYH1) is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPAR
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c7157a91ef1ca67a220eb105e525d4e
https://doi.org/10.1007/s40261-013-0128-3
Zobrazit plný text záznamu
6
A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy
Autor: Harsh Toshniwal, Shashank R Joshi, Alka Deshpande, Rajendrakumar H. Jani
Publikováno v: PLoS ONE, Vol 11, Iss 1, p e0146222 (2016)
PLoS ONE
Objective This study was designed to explore the efficacy and safety of saroglitazar 4 mg on hypertriglyceridemia in patients with HIV associated lipodystrophy. Methods During this 12-week prospective, multi-centric, open-label, single arm explorator
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46e033ec2d4846c8337d2b1cd155ef59
http://europepmc.org/articles/PMC4720399?pdf=render
Zobrazit plný text záznamu
8
A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI)
Autor: Anil Bhansali, Pramod Jha, Rajendrakumar H. Jani, Vikas Pai, Shashank R Joshi, Satinath Mukhopadhyay, Gunjan Jariwala
Publikováno v: Diabetes technologytherapeutics. 16(2)
Dyslipidemia due to diabetes is characterized by hypertriglyceridemia and reduced levels of high-density lipoprotein cholesterol (HDL-C) and elevated or normal levels of low-density lipoprotein cholesterol (LDL-C) in type 2 diabetes mellitus (T2DM).
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e354f4aac121841174e4e7e454b930d6
https://pubmed.ncbi.nlm.nih.gov/24138536
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje